– Reuters
BioDelivery Sciences Reports Mixed Q2 Earnings, Sees FY21 Belbuca Sales At Lower End Of Guidance Range
BioDelivery Sciences International Inc (NASDAQ:BDSI) has reported Q2 sales of $41.4 million, + 13.3% Y/Y, missing the consensus of $42.4…